225 related articles for article (PubMed ID: 33452660)
61. Does the public know when a scientific controversy is over? Public perceptions of hydroxychloroquine in France between April 2020 and June 2021.
Schultz É; Atlani-Duault L; Peretti-Watel P; Ward JK
Therapie; 2022; 77(5):591-602. PubMed ID: 35101281
[TBL] [Abstract][Full Text] [Related]
62. The additive effects of hydroxychloroquine to maintenance therapy with standard of care in patients with systemic lupus erythematosus.
Miyagawa I; Nakano K; Nakayamada S; Iwata S; Hanami K; Fukuyo S; Kubo S; Kawabe A; Miyazaki Y; Inoue Y; Ueno M; Ohkubo N; Fujita Y; Tanaka Y
Int J Rheum Dis; 2020 Apr; 23(4):549-558. PubMed ID: 32020727
[TBL] [Abstract][Full Text] [Related]
63. Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19.
Meo SA; Klonoff DC; Akram J
Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4539-4547. PubMed ID: 32373993
[TBL] [Abstract][Full Text] [Related]
64. Chloroquine- and Hydroxychloroquine-Induced Cardiomyopathy: A Case Report and Brief Literature Review.
Nadeem U; Raafey M; Kim G; Treger J; Pytel P; N Husain A; Schulte JJ
Am J Clin Pathol; 2021 May; 155(6):793-801. PubMed ID: 33316045
[TBL] [Abstract][Full Text] [Related]
65. Hydroxychloroquine: a multifaceted treatment in lupus.
Costedoat-Chalumeau N; Dunogué B; Morel N; Le Guern V; Guettrot-Imbert G
Presse Med; 2014 Jun; 43(6 Pt 2):e167-80. PubMed ID: 24855048
[TBL] [Abstract][Full Text] [Related]
66. "H" is not for hydroxychloroquine-"H" is for heparin: lack of efficacy of hydroxychloroquine and the role of heparin in COVID-19-preliminary data of a prospective and interventional study from Brazil.
de Oliveira Costa R; Nascimento JS; Reichert CO; da Costa APA; Dos Santos MAP; Soares AM; Tomé CEM; Hayden RL; Dos Santos CW; Barreiro B; El-Khatib AAB; de Pádua Covas Lage LA; Pereira J; Benetti MM
BMC Infect Dis; 2022 Feb; 22(1):120. PubMed ID: 35120461
[TBL] [Abstract][Full Text] [Related]
67. Proactive Prophylaxis With Azithromycin and HydroxyChloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID): A structured summary of a study protocol for a randomised controlled trial.
Sivapalan P; Ulrik CS; Bojesen RD; Lapperre TS; Eklöf JV; Håkansson KEJ; Browatzki A; Tidemansen C; Wilcke JT; Janner J; Gottlieb V; Meteran H; Porsbjerg C; Madsen BL; Moberg M; Pedersen L; Benfield TL; Lundgren JD; Knop FK; Biering-Sørensen T; Ghanizada M; Sonne TP; Bødtger UCS; Jensen SG; Rasmussen DB; Brøndum E; Tupper OD; Sørensen SW; Alstrup G; Laursen CB; Møller UW; Sverrild A; Jensen JS
Trials; 2020 Jun; 21(1):513. PubMed ID: 32522282
[TBL] [Abstract][Full Text] [Related]
68. Optimization of hydroxychloroquine dosing scheme based on COVID-19 patients' characteristics: a review of the literature and simulations.
Karatza E; Ismailos G; Marangos M; Karalis V
Xenobiotica; 2021 Feb; 51(2):127-138. PubMed ID: 32933365
[TBL] [Abstract][Full Text] [Related]
69. Effects of Hydroxychloroquine on endOthelial function in eLDerly with sleep apnea (HOLD): study protocol for a randomized clinical trial.
Tedesco Silva LM; Cortes A; Rossi B; Boll L; Waclawovsky G; Eibel B; Cadaval Gonçalves S; Irigoyen MC; Martinez D
Trials; 2021 Sep; 22(1):638. PubMed ID: 34535165
[TBL] [Abstract][Full Text] [Related]
70. Longterm Hydroxychloroquine Therapy and Low-dose Aspirin May Have an Additive Effectiveness in the Primary Prevention of Cardiovascular Events in Patients with Systemic Lupus Erythematosus.
Fasano S; Pierro L; Pantano I; Iudici M; Valentini G
J Rheumatol; 2017 Jul; 44(7):1032-1038. PubMed ID: 28507183
[TBL] [Abstract][Full Text] [Related]
71. Molecular Networking for Drug Toxicities Studies: The Case of Hydroxychloroquine in COVID-19 Patients.
Ferron PJ; Le Daré B; Bronsard J; Steichen C; Babina E; Pelletier R; Hauet T; Morel I; Tarte K; Reizine F; Clément B; Fromenty B; Gicquel T
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008505
[TBL] [Abstract][Full Text] [Related]
72. Hydroxychloroquine desensitization, an effective method to overcome hypersensitivity-a multicenter experience.
Tal Y; Maoz Segal R; Langevitz P; Kivity S; Darnizki Z; Agmon-Levin N
Lupus; 2018 Apr; 27(5):703-707. PubMed ID: 28992797
[TBL] [Abstract][Full Text] [Related]
73. Hydroxychloroquine-induced pigmentation in patients with systemic lupus erythematosus: a case-control study.
Jallouli M; Francès C; Piette JC; Huong du LT; Moguelet P; Factor C; Zahr N; Miyara M; Saadoun D; Mathian A; Haroche J; De Gennes C; Leroux G; Chapelon C; Wechsler B; Cacoub P; Amoura Z; Costedoat-Chalumeau N;
JAMA Dermatol; 2013 Aug; 149(8):935-40. PubMed ID: 23824340
[TBL] [Abstract][Full Text] [Related]
74. Concerns and needs of patients with systemic lupus erythematosus regarding hydroxychloroquine supplies during the COVID-19 pandemic: results from a patient-centred survey.
Plüß M; Chehab G; Korsten P
Ann Rheum Dis; 2021 Apr; 80(4):e52. PubMed ID: 32616604
[No Abstract] [Full Text] [Related]
75. Early cutaneous eruptions after oral hydroxychloroquine in a lupus erythematosus patient: A case report and review of the published work.
Matsuda T; Ly NTM; Kambe N; Nguyen CTH; Ueda-Hayakawa I; Son Y; Okamoto H
J Dermatol; 2018 Mar; 45(3):344-348. PubMed ID: 29239026
[TBL] [Abstract][Full Text] [Related]
76. Zebra-like bodies in COVID-19: is phospholipidosis evidence of hydroxychloroquine induced acute kidney injury?
Obeidat M; Isaacson AL; Chen SJ; Ivanovic M; Holanda D
Ultrastruct Pathol; 2020 Nov; 44(4-6):519-523. PubMed ID: 33274661
[TBL] [Abstract][Full Text] [Related]
77. Safety, Tolerability, and Pharmacokinetics of Nebulized Hydroxychloroquine: A Pilot Study in Healthy Volunteers.
Hawari F; Dodin Y; Tayyem R; Najjar S; Kakish H; Fara MA; Zou'bi AA; Idkaidek N
J Aerosol Med Pulm Drug Deliv; 2023 Apr; 36(2):76-81. PubMed ID: 36637803
[No Abstract] [Full Text] [Related]
78. Response to: 'Concerns and needs of patients with systemic lupus erythematosus regarding hydroxychloroquine supplies during the COVID-19 pandemic: results from a patient-centred survey' by Plüß
Mathian A; Amoura Z
Ann Rheum Dis; 2021 Apr; 80(4):e53. PubMed ID: 32616603
[No Abstract] [Full Text] [Related]
79. A Systematic Review and Meta-Analysis of the Safety of Hydroxychloroquine in a Randomized Controlled Trial and Observational Studies.
Konwar M; Maurya M; Thatte UM; Gogtay NJ; Bose D
Curr Rev Clin Exp Pharmacol; 2022; 17(3):216-235. PubMed ID: 34455948
[TBL] [Abstract][Full Text] [Related]
80. Correspondence on 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine'.
Martelli Júnior H; Marques NP; Marques NCT; Gomes de Lucena E; Martelli DRB; Oliveira EA
Ann Rheum Dis; 2023 Nov; 82(11):e225. PubMed ID: 33883160
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
